ESPERITE N.V. (Euronext: ESP, “Esperite”, “the Company” or “the Group”) has published today its Annual Report for the year ended 31 December 2017. The 2017 Annual Report is now available on the Company’s website www.esperite.com.
- CryoSave’s EBITDA turned positive from € -0.7 million to € 1.3 million.
- Genoma with AGAATA made strong technological progress despite the liquidation of the Swiss Genoma SA. AGAATA in its latest 3rd version is the state of the art in Genetic Diagnostic technology.
- The Cell Factory, who had a busy year initiating the first-in-man clinical trials in treatment of Crohn’s disease with EVs technology, obtained its patent granted in China, Canada and Europe for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology. The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke.
- Consolidated EBITDA improved from € -5.0 million to € -4.5 million. This improvement is in line with the improvement of operating cash flow before working capital movements which improved from € -5.0 million to € -4.4 million. As a result of the investments by European Select Growth Opportunities Fund the cash position increased by € 0.3 million.
- Esperite’s consolidated revenue decreased by 37% to € 16.6 million however the gross margin increased by 10% from 56% to 66% as a result of termination of several distribution agreements with partners in countries which were loss making or cash flow negative. Furthermore Esperite has redefined its geographic footprint, optimized the teams, adjusted the balance between B2B and B2C and brought in sophisticated commercial tools.
- Consolidated result amounted to € -12.9 million compared to € -8.5 million. This decrease is mainly due to impairment losses amounting to € 5.6 million in 2017 compared to € 1.0 million in 2016.
- The results of the not consolidated interests of the Company contributed € 0.7 million positively to the 2017 results compared to a negative contribution amounting to € 0.3 in 2016.
- Although liquidity remains an issue for the Company management feels confident about the going concern as a result of additional financing which has been secured in 2018 amounting to € 5.0 million from European Select Growth Opportunities Fund with a duration of 2 years. This financing is subject to certain conditions.
Amsterdam, The Netherlands – 23 November 2018